Artiria Medical secures significant funding to advance stroke treatment
Life sciences
6 March 2024
Artiria Medical’s deflectable guidewire provides an actively deformable tip and enhanced dynamic in-situ control resulting in seamless access to neurovascular targets. | © Artiria Medical
Pioneering neurovascular medtech start-up Artiria Medical has secured USD 6.5 million, a crucial funding to enhance minimally invasive surgical interventions for stroke patients.
Artiria Medical, the pioneering neurovascular medtech start-up based at the EPFL Innovation Park, has achieved a significant milestone by securing USD 6.5 million in its series A2 funding round. Spearheaded by 4FOX Ventures, this latest financial infusion, which includes a 0.5 million Tech Growth Loan from the Foundation for Technological Innovation (FIT), marks a crucial phase in Artiria’s mission to enhance minimally invasive surgical interventions for stroke patients.
With a notable track record that includes raising CHF 3.8 million to forward clinical and regulatory deployment and securing a substantial EIC accelerator grant, Artiria is steering towards a revolutionary approach in stroke treatment. The company’s flagship product, a novel real-time deflectable guidewire, has already been utilized in human patients and received FDA clearance, is set to transform neurointerventional surgeries by offering enhanced access to diseased sites, promising faster and more effective treatment for stroke sufferers.
Significant broadening of Artiria’s global impact
The Series A2 funding will facilitate the completion of crucial clinical studies in both Europe and the United States. These studies aim to validate the unique advantages of Artiria’s product against leading market products through randomized controlled trials. Guillaume Petit-Pierre, CEO and co-founder, envisions this strategic step as pivotal in advancing towards European market approval, significantly broadening Artiria’s global impact.
Valentin Chenaux, General Partner of 4FOX Ventures, expressed enthusiasm for Artiria’s potential to innovate stroke treatment, emphasizing the solution’s capacity to enable safer and quicker procedures. This sentiment is echoed by the involvement of the Wyss Center for Bio and Neuroengineering and existing investors such as Verve Ventures, the Zürcher Kantonalbank, NEST pension fund, and business angels, all of whom have reaffirmed their confidence in Artiria’s vision and technology.
